antivirals

Update on Oral Antivirals for COVID-19 Management




antivirals

Market for Smart Antivirals and Antibacterials to Grow to US $1.3 Billion by 2025

COVID-19 has propelled the market for antimicrobials of all types over the past year, this n-tech study takes a look at business potential for smart materials with antimicrobial functionality in a post vaccine world.




antivirals

Exploring 7β-amino-6-nitrocholestens as COVID-19 antivirals: in silico, synthesis, evaluation, and integration of artificial intelligence (AI) in drug design: assessing the cytotoxicity and antioxidant activity of 3β-acetoxynitrocholestane

RSC Med. Chem., 2024, Advance Article
DOI: 10.1039/D4MD00257A, Research Article
Shahabuddin, Uzma, Mohammad Azam, Mehtab Parveen, Nurul Huda Abd Kadir, Kim Min, Mahboob Alam
In light of the ongoing pandemic caused by SARS-CoV-2, effective and clinically translatable treatments are desperately needed for COVID-19 and its emerging variants.
To cite this article before page numbers are assigned, use the DOI form of citation above.
The content of this RSS Feed (c) The Royal Society of Chemistry




antivirals

New antivirals for Hepatitis C - what does the evidence prove?

There’s been a lot of attention given to the new antirviral drugs which target Hepatitis C - partly because of the burden of infection of the disease, and the lack of a treatment that can be made easily accessible to around the world, and partly because of the incredible cost of a course of treatment. But a new article on BMJ talks about the...




antivirals

How big pharma firms are quietly collaborating on new coronavirus antivirals

Behind the scenes, companies including Novartis, Takeda, and Gilead are collaborating in a loose alliance. Their work might not be done in time to stop COVID-19, but they hope it can prevent the next pandemic